

Künstliche Sauerstoffträger - Wie lange müssen wir noch warten?

1. Liumbruno GM, Vaglio S, Grazzini G, Spahn DR, Biancofiore G. Patient blood management: a fresh look at a new approach to blood transfusion. *Minerva Anesthesiol.* 2014.
2. Rohde JM, Dimcheff DE, Blumberg N, et al. Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. *JAMA.* 2014;311(13):1317-1326.
3. Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. *Cochrane Database Syst Rev.* 2012;4:CD002042.
4. Salunkhe V, van der Meer PF, de Korte D, Seghatchian J, Gutierrez L. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. *Transfus Apher Sci.* 2015;52(1):19-34.
5. Simoni J. New approaches in commercial development of artificial oxygen carriers. *Artif Organs.* 2014;38(8):621-624.
6. Wang D, Sun J, Solomon SB, Klein HG, Natanson C. Transfusion of older stored blood and risk of death: a meta-analysis. *Transfusion.* 2012;52(6):1184-1195.
7. Holcomb JB, Donathan DP, Cotton BA, et al. Prehospital Transfusion of Plasma and Red Blood Cells in Trauma Patients. *Prehosp Emerg Care.* 2015;19(1):1-9.
8. Lasocki S, Krauspe R, von Heymann C, Mezzacasa A, Chainey S, Spahn DR. PREPARE: the prevalence of perioperative anaemia and need for patient blood management in elective orthopaedic surgery: a multicentre, observational study. *Eur J Anaesthesiol.* 2015;32(3):160-167.
9. Williamson LM, Devine DV. Challenges in the management of the blood supply. *Lancet.* 2013;381(9880):1866-1875.
10. Robich MP, Koch CG, Johnston DR, et al. Trends in blood utilization in United States cardiac surgical patients. *Transfusion.* 2014.
11. Institut P-E. Bericht zur Meldung nach §21 Transfusionsgesetz. In: 7/4 F, ed. Langen: Paul-Ehrlich Institut; 2014.
12. Bian Y, Wei G, Chang TM. Lowering of elevated tissue PCO₂ in a hemorrhagic shock rat model after reinfusion of a novel nanobiotechnological polyhemoglobin-superoxide dismutase-catalase-carbonic anhydrase that is an oxygen and a carbon dioxide carrier with enhanced antioxidant properties. *Artif Cells Nanomed Biotechnol.* 2013;41(1):60-68.
13. Lewis CJ, Ross JD. Hemoglobin-based oxygen carriers: an update on their continued potential for military application. *J Trauma Acute Care Surg.* 2014;77(3 Suppl 2):S216-221.
14. Tao Z, Ghoroghchian PP. Microparticle, nanoparticle, and stem cell-based oxygen carriers as advanced blood substitutes. *Trends Biotechnol.* 2014;32(9):466-473.
15. Scurtu VF, Mot AC, Silaghi-Dumitrescu R. Protein-based blood substitutes: recent attempts at controlling pro-oxidant reactivity with and beyond hemoglobin. *Pharmaceuticals (Basel).* 2013;6(7):867-880.
16. Lui FE, Kluger R. Reviving artificial blood: meeting the challenge of dealing with NO scavenging by hemoglobin. *ChemBiochem.* 2010;11(13):1816-1824.
17. Buehler PW, D'Agnillo F, Schaer DJ. Hemoglobin-based oxygen carriers: From mechanisms of toxicity and clearance to rational drug design. *Trends Mol Med.* 2010;16(10):447-457.
18. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. *JAMA.* 2008;299(19):2304-2312.
19. Centis V, Vermette P. Enhancing oxygen solubility using hemoglobin- and perfluorocarbon-based carriers. *Front Biosci (Landmark Ed).* 2009;14:665-688.
20. Scholer M, Frietsch T, Jambor C, Knels R. [Artificial blood - coming soon or never reaching clinical maturity?]. *Dtsch Med Wochenschr.* 2010;135(12):575-581.
21. Modery-Pawlowski CL, Tian LL, Pan V, Sen Gupta A. Synthetic approaches to RBC mimicry and oxygen carrier systems. *Biomacromolecules.* 2013;14(4):939-948.
22. Chang TM. Therapeutic applications of polymeric artificial cells. *Nat Rev Drug Discov.* 2005;4(3):221-235.
23. Varnado CL, Mollan TL, Birukou I, Smith BJ, Henderson DP, Olson JS. Development of recombinant hemoglobin-based oxygen carriers. *Antioxid Redox Signal.* 2013;18(17):2314-2328.
24. Tsai AG, Intaglietta M, Sakai H, et al. Microcirculation and NO-CO studies of a natural extracellular hemoglobin developed for an oxygen therapeutic carrier. *Curr Drug Discov Technol.* 2012;9(3):166-172.

25. Elmer J, Palmer AF, Cabrales P. Oxygen delivery during extreme anemia with ultra-pure earthworm hemoglobin. *Life Sci.* 2012;91(17-18):852-859.
26. Le Gall T, Polard V, Rousselot M, et al. In vivo biodistribution and oxygenation potential of a new generation of oxygen carrier. *J Biotechnol.* 2014;187:1-9.
27. Tsuchida E, Sou K, Nakagawa A, Sakai H, Komatsu T, Kobayashi K. Artificial oxygen carriers, hemoglobin vesicles and albumin-hemes, based on bioconjugate chemistry. *Bioconjug Chem.* 2009;20(8):1419-1440.
28. Kano K, Kitagishi H. HemoCD as an artificial oxygen carrier: oxygen binding and autoxidation. *Artif Organs.* 2009;33(2):177-182.
29. Huang Y, Komatsu T, Wang RM, Nakagawa A, Tsuchida E. Poly(ethylene glycol)-conjugated human serum albumin including iron porphyrins: surface modification improves the O₂-transporting ability. *Bioconjug Chem.* 2006;17(2):393-398.
30. Harrington JP, Wollocko J, Kostecki E, Wollocko H. Physicochemical characteristics of OxyVita hemoglobin, a zero-linked polymer: liquid and powder preparations. *Artif Cells Blood Substit Immobil Biotechnol.* 2011;39(1):12-18.
31. Reynolds PS, Barbee RW, Skafien MD, Ward KR. Low-volume resuscitation cocktail extends survival after severe hemorrhagic shock. *Shock.* 2007;28(1):45-52.
32. Hsia CJ, Ma L. A hemoglobin-based multifunctional therapeutic: polynitroxylated pegylated hemoglobin. *Artif Organs.* 2012;36(2):215-220.
33. Brockman EC, Bayir H, Blasiole B, et al. Polynitroxylated-pegylated hemoglobin attenuates fluid requirements and brain edema in combined traumatic brain injury plus hemorrhagic shock in mice. *J Cereb Blood Flow Metab.* 2013;33(9):1457-1464.
34. Bian Y, Rong Z, Chang TM. Polyhemoglobin-superoxide dismutase-catalase-carbonic anhydrase: a novel biotechnology-based blood substitute that transports both oxygen and carbon dioxide and also acts as an antioxidant. *Artif Cells Blood Substit Immobil Biotechnol.* 2011;39(3):127-136.
35. Bian Y, Chang TM. A novel nanobiotherapeutic poly-[hemoglobin-superoxide dismutase-catalase-carbonic anhydrase] with no cardiac toxicity for the resuscitation of a rat model with 90 minutes of sustained severe hemorrhagic shock with loss of 2/3 blood volume. *Artif Cells Nanomed Biotechnol.* 2015;43(1):1-9.
36. Sakai H, Sou K, Horinouchi H, Kobayashi K, Tsuchida E. Hemoglobin-vesicle, a cellular artificial oxygen carrier that fulfils the physiological roles of the red blood cell structure. *Adv Exp Med Biol.* 2010;662:433-438.
37. Seishi Y, Horinouchi H, Sakai H, Kobayashi K. Effect of the cellular-type artificial oxygen carrier hemoglobin vesicle as a resuscitative fluid for prehospital treatment: experiments in a rat uncontrolled hemorrhagic shock model. *Shock.* 2012;38(2):153-158.
38. Saito Y, Suzuki Y, Yamanashi Y, Terajima K, Sakamoto A, Kondo Y. The impact on renal function of fluid resuscitation with hemoglobin vesicle solution in moderate hemorrhagic shock. *J Artif Organs.* 2013;16(3):376-381.
39. Ogata Y, Goto H, Kimura T, Fukui H. Development of neo red cells (NRC) with the enzymatic reduction system of methemoglobin. *Artif Cells Blood Substit Immobil Biotechnol.* 1997;25(4):417-427.
40. Ikegawa H, Kuwagata Y, Hayakawa K, Noguchi K, Ogura H, Sugimoto H. Effects of exchange transfusion with liposome-encapsulated hemoglobin on VO₂/DO₂. *Artif Organs.* 2012;36(2):130-138.
41. Kawaguchi AT, Haida M, Ohba H, Yamano M, Fukumoto D, Tsukada H. Liposome-encapsulated hemoglobin ameliorates ischemic stroke in nonhuman primates: longitudinal observation. *Artif Organs.* 2013;37(10):904-912.
42. Yadav VR, Nag O, Awasthi V. Biological evaluation of liposome-encapsulated hemoglobin surface-modified with a novel PEGylated nonphospholipid amphiphile. *Artif Organs.* 2014;38(8):625-633.
43. Shimbo D, Abumiya T, Shichinohe H, Nakayama N, Kazumata K, Houkin K. Post-ischemic intra-arterial infusion of liposome-encapsulated hemoglobin can reduce ischemia reperfusion injury. *Brain Res.* 2014;1554:59-66.
44. Xiong Y, Liu ZZ, Georgieva R, et al. Nonvasoconstrictive hemoglobin particles as oxygen carriers. *ACS Nano.* 2013;7(9):7454-7461.
45. Baumler H, Xiong Y, Liu ZZ, Patzak A, Georgieva R. Novel hemoglobin particles--promising new-generation hemoglobin-based oxygen carriers. *Artif Organs.* 2014;38(8):708-714.
46. Chen JY, Scerbo M, Kramer G. A review of blood substitutes: examining the history, clinical trial results, and ethics of hemoglobin-based oxygen carriers. *Clinics (Sao Paulo).* 2009;64(8):803-813.
47. Kocian R, Spahn DR. Haemoglobin, oxygen carriers and perioperative organ perfusion. *Best Pract Res Clin Anaesthesiol.* 2008;22(1):63-80.
48. Sloan EP, Koenigsberg M, Gens D, et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. *JAMA.* 1999;282(19):1857-1864.
49. Kerner T, Ahlers O, Veit S, et al. DCL-Hb for trauma patients with severe hemorrhagic shock: the European „On-Scene“ multicenter study. *Intensive Care Med.* 2003;29(3):378-385.

50. Elmer J, Alam HB, Wilcox SR. Hemoglobin-based oxygen carriers for hemorrhagic shock. *Resuscitation*. 2012;83(3):285-292.
51. Sloan EP, Koenigsberg MD, Philbin NB, Gao W, Group DCTHSS, European HI. Diaspirin cross-linked hemoglobin infusion did not influence base deficit and lactic acid levels in two clinical trials of traumatic hemorrhagic shock patient resuscitation. *J Trauma*. 2010;68(5):1158-1171.
52. Sloan EP, Philbin NB, Koenigsberg MD, Gao W, Group DCTHSS, European HI. The lack of consistent diaspirin cross-linked hemoglobin infusion blood pressure effects in the US and EU traumatic hemorrhagic shock clinical trials. *Shock*. 2010;33(2):123-133.
53. Kinasewitz GT, Privalle CT, Imm A, et al. Multicenter, randomized, placebo-controlled study of the nitric oxide scavenger pyridoxalated hemoglobin polyoxyethylene in distributive shock. *Crit Care Med*. 2008;36(7):1999-2007.
54. Moore EE, Moore FA, Fabian TC, et al. Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial. *J Am Coll Surg*. 2009;208(1):1-13.
55. Ortiz D, Barros M, Yan S, Cabrales P. Resuscitation from hemorrhagic shock using polymerized hemoglobin compared to blood. *Am J Emerg Med*. 2014;32(3):248-255.
56. Serruys PW, Vranckx P, Slagboom T, et al. Haemodynamic effects, safety, and tolerability of haemoglobin-based oxygen carrier-201 in patients undergoing PCI for CAD. *EuroIntervention*. 2008;3(5):600-609.
57. Simoni J, Simoni G, Moeller JF, Feola M, Wesson DE. Artificial oxygen carrier with pharmacologic actions of adenosine-5'-triphosphate, adenosine, and reduced glutathione formulated to treat an array of medical conditions. *Artif Organs*. 2014;38(8):684-690.
58. Misra H, Lickliter J, Kazo F, Abuchowski A. PEGylated carboxyhemoglobin bovine (SANGUINATE): results of a phase I clinical trial. *Artif Organs*. 2014;38(8):702-707.
59. Riess JG. Understanding the fundamentals of perfluorocarbons and perfluorocarbon emulsions relevant to in vivo oxygen delivery. *Artif Cells Blood Substit Immobil Biotechnol*. 2005;33(1):47-63.
60. Kuznetsova IN. Drug Synthesis Methods and Manufacturing Technologies, Perfluorocarbon Emulsions: Stability in vitro and in vivo (A Review). *Pharmaceutical Chemistry Journal*. 2003;37(8):20-25.
61. Spiess BD. Perfluorocarbon emulsions as a promising technology: a review of tissue and vascular gas dynamics. *J Appl Physiol* (1985). 2009;106(4):1444-1452.
62. Cabrales P, Intaglietta M. Blood substitutes: evolution from noncarrying to oxygen- and gas-carrying fluids. *ASAIO J*. 2013;59(4):337-354.
63. Yokoyama K. Effect of perfluorochemical (PFC) emulsion on acute carbon monoxide poisoning in rats. *Jpn J Surg*. 1978;8(4):342-352.
64. Lowe KC. Blood substitutes: from chemistry to clinic. *Journal of Materials Chemistry*. 2006;16:4189-4196.
65. Riess JG. Oxygen carriers („blood substitutes“)--raison d'etre, chemistry, and some physiology. *Chem Rev*. 2001;101(9):2797-2920.
66. Castro CI, Briceno JC. Perfluorocarbon-based oxygen carriers: review of products and trials. *Artif Organs*. 2010;34(8):622-634.
67. Shaw RF, Richard TJ. Rational Development of Oxyfluor. In: Winslow RM, ed. *Blood Substitutes*. London: Elsevier; 2006:298-311.
68. Keipert PE. Oxygent, a Perfluorochemical-Based Oxygen Therapeutic for Surgical Patients. In: Winslow RM, ed. *Blood Substitutes*. London: Elsevier; 2006:312-323.
69. Spahn DR, Waschke KF, Standl T, et al. Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood-loss non-cardiac surgery: results of a European phase 3 study. *Anesthesiology*. 2002;97(6):1338-1349.
70. Hill SE, Grocott HP, Leone BJ, White WD, Newman MF, Neurologic Outcome Research Group of the Duke Heart C. Cerebral physiology of cardiac surgical patients treated with the perfluorocarbon emulsion, AF0144. *Ann Thorac Surg*. 2005;80(4):1401-1407.
71. Mattrey RF. Are cerebral emboli real when perfluorocarbon emulsion (AF0144) is used in cardiac surgery? *Ann Thorac Surg*. 2007;83(5):1922-1923; author reply 1923.
72. Hou S, Ding H, Lv Q, et al. Therapeutic effect of intravenous infusion of perfluorocarbon emulsion on LPS-induced acute lung injury in rats. *PLoS One*. 2014;9(1):e87826.
73. Oxygen Biotherapeutics Announces Halt of Oxycyte Phase IIb Traumatic Brain Injury Trial [press release]. Morrisville, N.C.: Tenax Therapeutics, 09/11/2014 2014.
74. Perftoran. Perftoran. 2015; <http://www.perftoran.ru/index.php/en/>. Accessed 06/02/2015, 2015.
75. Maevsky EI, Ivanitsky HR, Islamov BI, et al. Perftoran. In: Winslow RM, ed. *Blood Substitutes*. London: Elsevier; 2006:288-297.